Landscapes / Signs and Symptoms

Digestive Signs and Symptoms

25 drugs in active Digestive Signs and Symptoms trials · Updated 20 Nov 2026

Furthest along
3 approved
10 in Phase 3
Next Phase 3 result
1 Dec 2026
Drugs
25
In active trials, any stage
Trials
30 active
12 sub-diseases included

Drugs25

DrugHow it worksCompanyStageNext dateDetails
—
Phase 3 1 Dec 2026soonPhase 3 trial completes
Cell therapy
Phase 3 Dec 2026Phase 3 trial completes
Dopamine and norepinephrine reuptake inhibitor
Phase 3 Dec 2026Phase 3 trial completes
Monoclonal antibody
Pfizer · Public PFE
Phase 2/3 23 Jan 2028Phase 2/3 trial completes
—
Phase 2/3 Mar 2028Phase 2/3 trial completes
Calcitonin gene-related peptide receptor antagonist
Pfizer · Public PFE
Phase 3 9 Jan 2029Phase 3 trial completes
Monoclonal antibody
Phase 2/3 Dec 2029Phase 2/3 trial completes
Unmodified immunoglobulin
Phase 2/3 Mar 2030Phase 2/3 trial completes
—
Phase 3 —
—
Phase 3 —

See all 25 drugs

Sign in free to see the whole list. No card, no password.

Sign in free

Included12

Sub-diseaseDrugsActive trialsTrials
Nausea
1 sub-disease
68
Vomiting
2 sub-diseases
77
Diarrhea
1 sub-disease
55
Anorexia34
Constipation
1 sub-disease
33
Hyperphagia33
Feeding and Eating Disorders
2 sub-diseases
12
Abdominal Pain
1 sub-disease
11
Dyspepsia11
Encopresis11

2 more with no active trials: Flatulence, Heartburn

About

Summary
25 drugs are in active Digestive Signs and Symptoms trials: 3 approved, 10 in Phase 3, 12 earlier. The next Phase 3 result expected is Tradipitant’s, 1 Dec 2026. Updated 20 Nov 2026.
Registry term
Signs and Symptoms, Digestive
Counts
Active trials the registry tags with the term or a term under it, at any stage. A search also reads trial titles and drug names, so its counts differ.
Sources
ClinicalTrials.gov updated 20 Nov 2026